Arsenic trioxide

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc | ATC codes: L01XX27

Indication	Acute myeloid leukaemia with recurrent genetic abnormalities ICD11 code: 2A60.0
Medicine type	Chemical agent
List type	Complementary
Formulations	**Parenteral > General injections > IV:** 1 mg per mL concentrate for solution for infusion ; 2 mg per mL concentrate for solution for infusion
EML status history	First added in 2019 (TRS 1021) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Wikipedia	Arsenic trioxide
DrugBank	Arsenic trioxide

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of additional strength dosage form of aresnic trioxde (concentrate for solution for infusion 2 mg/mL) to the EML and EMLc.